Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 7, 2004, Pages 406-415

  Poli, Giorgio ^a   Martino, Piera Anna ^a   Villa, Stefania ^a   Carcassola, Gabriela ^a   Giannino, Maria Laura ^a   Dall'Ara, Paola ^a   Pollera, Claudia ^a   Iussich, Selina ^b   Tranquillo, Vito M ^c   Bareggi, Silvio ^a   Mantegazza, Paolo ^a   Ponti, Wilma ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA LOMBARDIA E DELL EMILIA ROMAGNA   (Italy)

^d Dipartimento di Patologia Animale   (Italy)

Author keywords

Bovine spongiform encephalopatdy (BSE); CAS 573 58 0; Congo Red, anti prion activity, derivatives, hamster; Prion protein

Indexed keywords

ANTIVIRUS AGENT; BENZIDINE(4,4' DIAMINOBIPHENYL); CAS 573580; CONGO RED; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPRION ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; EXPERIMENTAL INFECTION; FEMALE; HAMSTER; IN VITRO STUDY; NONHUMAN; PRION DISEASE; SCRAPIE; SURVIVAL;

EID: 3242786318     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296992     Document Type: Article

References (63)

1. Aguzzi, A., Montrasio, F., Kaeser, P. S., Prions: health scare and biological challenge. Nat. Rev. Mol. Cell Biol. 2, 118 (2001)
2. Ashby, J., Styles, J., Callander, R. D., Comparative activity of 4,4′diaminobiphenyl (benzidine) and its terphenyl analogue, 4,4′-diaminoterphenyl, in two in vitro assays for potential carcinogenicity. Carcinogenesis 1, 801 (1980)
3. Bandiera, T., Lansen, J., Post, G. et al., Inhibitors of Ab peptide aggregation as potential anti-Alzheimer agents. Curr. Med. Chem. 4, 159 (1997)
4. Beringue, V., Adjou, K. T., Lamoury, F. et al., Opposite effects of Dextran Sulfate 500, the polyene antibiotic MS-8209, and Congo Red on accumulation on the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent. J. Virol. 74, 5432 (2000)
5. Bos, R. P, Koopman, J. P., Theuws, J. L., The essential role of the intestinal flora in the toxification of orally-administered benzidine-based dyes: internal exposure of rats to benzidine after intestinal azo reduction. Mutat. Res. 181, 327 (1987)
6. Bosque, P. J., Prusiner, S. B., Cultured cells sublines highly susceptible to prion infection. J. Virol. 74, 4377 (2000)
7. Brown, D. R., PrPsc-like prion protein peptide inhibits the function of cellular prion protein. Biochem. J. 352, 511 (2000)
8. Caspi, S., Halimi, M., Yanai, A. et al., The antiprion activity of Congo Red. Putative mechanism. J. Biol. Chem. 273, 3484 (1998)
9. Caughey, B., Brown, K., Raymond, G. J. et al., Binding of protease-sensitive form of prion protein PrP to sulfated glycosaminoglycan and Congo Red. J. Virol. 68, 2135 (1994)
10. Caughey, B., Chesebro, B., Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol. 7, 56 (1997)
11. Caughey, B., Race, R. E., Potent inhibition of scrapie-associated PrP accumulation by Congo Red. J. Neurochem. 59, 768 (1992)
12. Cohen, F. E., Prions, peptides and protein misfolding. Mol. Med. Today 6, 292 (2000)
13. Collinge, J., Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24, 519 (2001)
14. Demaimay, R., Adjou, K., Beringue, V. et al., Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J. Virol. 71, 9685 (1997)
15. Demaimay, R., Adjou, K., Lasmezas, C. et al., Pharmacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. J. Gen. Virol. 75, 2499 (1994)
16. Demaimay, R., Chesebro, B., Caughey, B., Inhibition of formation of protease-resistant prion protein by Trypan blue, Sirius Red and other Congo Red analogues. Arch. Virol. Suppl. 16, 277 (2000)
17. Demaimay, R., Harper, J., Gordon, H. et al., Structural aspects of Congo Red as an inhibitor of protease-resistant prion protein formation. J. Neurochem. 71, 2534 (1998)
18. Diringer, H., Ehlers, B. J., Chemoprophylaxis of scrapie in mice J. Gen. Virol. 72, 457 (1991)
19. Ehlers, B., Diringer, H., Dextran sulfate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J. Gen. Virol. 65, 1325 (1984)
20. Farquhar, C., Dickinson, A., Bruce, M., Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet 353, 117 (1999)
21. Frankena, K., Graat, E. A. M., Analysis of time risk (survival) data, J.P.T.M. Noordhuizen, K. Frankena, C. M. van der Hoof et al. (eds.), Application of quantitative methods in veterinary epidemiology, p. 181, Wageningen, Wageningen Pers, The Netherlands (1997)
22. Glatzel, M., Aguzzi, A., Peripheral pathogenesis of prion diseases. Microbes Infect. 2, 613 (2000)
23. Glenner, G., Amyloid deposits and amyloidosis. The beta-fibrilloses. N. Engl. J. Med. 302, 1333 (1980)
24. Grambsh, P. M., Therneau, T. M., Proportional hazard test and diagnostic based on weighted residual. Biometrika 81, 515 (1994)
25. Gray, L. E., Ostby, J. S., The effects of prenatal administration of azo dyes on testicular development in the mouse: structure activity profile of dyes derived from benzidine, dimethylbenzidine or dimethoxybenzidine. Fund. Appl. Toxicol. 20, 177 (1993)
26. Harris, D. A., Cellular biology of prion diseases. Clinical Microbiol. Rev. 12, 429 (1999)
27. Hill, A. F., Desbrulais, M., Joiner, S. et al., The same prion strain cause vCJD and BSE. Nature 389, 448 (1997)
28. Ingrosso, L., Ladogana, A., Pocchiari, M., Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol. 69, 506 (1995)
29. Kaneko, K., Zulianello, L., Scott, M. et al., Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. Natl. Acad. Sci. USA 94, 10069 (1997)
30. Kimberlin, R. H., Walker, C. A., The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch. Virol. 78, 9 (1983)
31. Kimberlin, R. H., Walker, C. A., Characteristics of a short incubation model of scrapie in the golden hamster. J. Gen. Viro. 34, 295 (1977)
32. Kimberlin, R. H., Walker, C. A., Pathogenesis of scrapie (strain 263K) in hamsters infected intracerebrally, intraperitoneally or intraocularly. J. Gen. Virol. 67, 255 (1986)
33. Kimberlin, R. H., Walker, C. A., Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob. Agents Chemother. 30, 409 (1986)
34. Klein, M. A., Frigg, R., Raeber, A. J. et al., A crucial role for B cells in neuroinvasive scrapie. Nature 390, 687 (1997)
35. Lazmesas, C. I., Cesbron, J. Y., Deslys, J. O. et al., Immune system-dependent and independent replication of the scrapie agent. J. Virol. 70, 1292 (1996)
36. Mangè, A., Nishida, N., Milhavet, O. et al., Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J. Virol. 74, 3135 (2000)
37. McBride, P. A., Eikelenboom, P., Kraal, G. et al., PrP protein is associated with FDC cells of spleens and lymphonodes in uninfected and scrapie-infected mice. J. Pathol. 168, 413 (1992)
38. Milhavet, O., Lehmann, S., Oxidative stress and the prion protein in transmissible spongiform encephalopathies. Brain Res. Rev. 38, 328 (2002)
39. Milhavet, O., Mangé, A., Casanova, D. et al., Effect of Congo Red on wild-type and mutated Prion Proteins in cultured cells, J. Neurochem. 74, 222 (2000)
40. Nishida, N., Harris, D. A., Vilette, D. et al., Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cells lines overexpressing wild-type mouse protein. J. Virol. 74, 320 (2000)
41. Pan, T., Colucci, M., Wong, B. S. et al., Novel differences between two human prion strains revealed by two dimensional gel electrophoresis. J. Biol. Chem. 276, 37284 (2001)
42. Perrier, V., Wallace, A. C., Kaneko, K. et al., Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc. Natl. Acad. Sci. USA 97, 6073 (2000)
43. Piccardo, P., Safar, J., Ceroni, M. et al., Immunohistochemical localization of prion protein in spongiform encephalopathies and normal brain tissues. Neurology 40, 518 (1990)
44. Pirola, R., Gervasoni, M., Pollera, C. et al., Determination of sodium 3,4-diaminonaphthalene-1-sulfonate, a Congo Red derivative, in plasma and brain of hamsters by high-performance liquid chromatography after solid-phase extraction and ultraviolet absorbance. J. Chromatog. B 769, 27 (2002)
45. Pocchiari, M., Schmittinger, S., Masullo, C., Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J. Gen. Virol. 68, 219 (1987)
46. Poli, G., Ponti, W., Carcassola, G. et al., In vitro evaluation of the anti-prionic activity of newly synthesized Congo Red derivatives. Arzneim.-Forsch./Drug Res. 53, 875 (2003)
47. Prusiner, S. B., Prions. Proc. Natl. Acad. Sci. USA 95, 13363 (1998)
48. Prusiner, S. B., Cochran, S. P., Groth, D. F. et al., Measurement of the scrapie agent using an incubation time assay. Ann. Neurol. 11, 353 (1982)
49. Race, R., Oldstone, M., Chesebro, B., Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J. Virol. 74, 828 (2000)
50. Reilly, C. E., Beta-sheet breaker peptides reverse conformation of pathogenic prion proteins. J. Neurol. 247, 319 (2000)
51. Rudyk, H., Vasiljevic, S., Hennion, R.M. et al., Screening Congo Red and its analogues for their ability to prevent the formation of PrPres in scrapie-infected cells. J. Gen. Virol. 81, 1155 (2000)
52. Shaked, G. R., Shaked, Y., Kariv-Inbal, Z. et al., A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. J. Biol. Chem. 276, 31479 (2001)
53. STATACORP, Stata Statistical Softwarw: Release 7.0, Stata Corporation, College Station, TX, USA (2001)
54. Supattapone, S., Nguyen, H. O., Cohen, F. E. et al., Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. USA 96, 14529 (1999)
55. Tagliavini, F., Forloni, G., Colombo, L. et al., Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J. Mol. Biol. 300, 1309 (2000)
56. Tagliavini, F., McArthur, R. A., Canciani, B. et al., Effectiveness of anthracycline against experimental prion disease in Syrian hamster. Science 276, 1119 (1997)
57. Talaska, G., Au, W. W., Ward, J. B. Jr et al., The correlation between DNA adducts and chromosomal aberrations in the target organ of benzidine exposed, partially-hepatectomized mice. Carcinogenesis 8, 1899 (1987)
58. Villa, S., Cignarella, G., Barlocco, D. et al., Congo red analogues as potential anti-prion agents. Il Farmaco 58, 929 (2003)
59. Will, R. G., Ironside, J. W., Zeidler, M. et al., A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921 (1996)
60. Windl, O., Lorenz, H., Behrens, C. et al., Construction and characterization of murine neuroblastoma cell clones allowing inducible and high expression of the prion protein. J. Gen. Virol. 80, 15 (1999)
61. Wong, B. S., Pan, T., Liu, T. et al., Prion disease: a loss of antioxidant function? Biochem. Biophys. Res. Com. 275, 249 (2000)
62. Ye, X., Scallet, A. C., Kascsak, R. J. et al., Astrocytosis and amyloid deposition in scrapie infected hamsters. Brain Res. 809, 277 (1998)
63. Zulianello, L., Kaneko, K., Scott, M. et al., Dominant-negative inhibition of prion formation diminished by deletion mutagenesis of the prion protein. J. Virol. 74, 4351 (2000)